| abstract |
A complement inhibitor, which is an anti-C5 antibody or a C5-binding fragment thereof, for use in a method of treating atypical hemolytic uremic syndrome (aHUS), the method comprising: (a) determining the concentration of at least two biomarker proteins associated with aHUS in a biological fluid obtained from a subject who has, is suspected of having or is at risk of developing aHUS, in which the biomarker proteins associated with aHUS are TNFR1 and at least one other biomarker protein associated with aHUS selected de: CXCL10, MCP-1, IFN-γ, IL-6, a proteolytic fragment of complement component factor B, soluble C5b9 (sC5b9), prothrombin fragment F1 + 2, d-dimer, thrombomodulin, VCAM-1, Factor von Willebrand (vWF), complement component C5a, ß2 (ß2M) microglobulin, clusterin, cystatin C, NAG, TIMP-1, NGAL, fatty acid binding protein 1 (FABP-1), albumin, CXCL9, KIM- 1, soluble CD40 ligand (sCD40L), ICAM-1, IL-1 beta, IL-12 p70, IL-8 and vascular endothelial cell growth factor (VEGF); and (b) administering the complement inhibitor to the subject in an amount and frequency sufficient to reduce the concentration of the at least two biomarker proteins associated with aHUS, compared to the concentration in a sample of biological liquid of the same type obtained from the subject before complement inhibitor treatment. |